Esperion Therapeutics Inc (ESPR)vsViatris Inc (VTRS)
ESPR
Esperion Therapeutics Inc
$3.18
0.00%
HEALTHCARE · Cap: $819.47M
VTRS
Viatris Inc
$16.51
+0.79%
HEALTHCARE · Cap: $19.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 3424% more annual revenue ($14.74B vs $418.24M). ESPR leads profitability with a -1.8% profit margin vs -2.8%. VTRS earns a higher WallStSmart Score of 48/100 (D+).
ESPR
Avoid34
out of 100
Grade: F
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ESPR.
Margin of Safety
-85.0%
Fair Value
$8.72
Current Price
$16.51
$7.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 23.2% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -260.8% — below average capital efficiency
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ESPR
The strongest argument for ESPR centers on Debt/Equity, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : ESPR
The primary concerns for ESPR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ESPR profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
ESPR carries more volatility with a beta of 1.06 — expect wider price swings.
ESPR is growing revenue faster at 23.2% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (48/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Esperion Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?